Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The increased need to avoid IMV in rural intermediate care units.
"Wednesday, January 31, 2024
NIH study shows higher mortality rates for patients on respiratory support in rural intermediate care units"
https://www.nih.gov/news-events/news-releases/nih-study-shows-higher-mortality-rates-patients-respiratory-support-rural-intermediate-care-units
"Survival without Ventilation (SWOV)" was the primary endpoint of the company's LIVE-AIR trial, and the just-released NIH study highlights the importance of getting lenz approved, especially for rural intermediate care units.
As covid hit, my best buys were in the 90 cent range.
04/24/2020 Buy
Trade Details HGEN
$0.91
04/24/2020 Buy
Trade Details HGEN
$0.999
My best sells were as follows.
03/29/2021 Sell
Trade Details HGEN
$27.78
03/29/2021 Sell
Trade Details HGEN
$29.07
My exits were on the day that Humanigen announced positive top line data of the LIVE-AIR trial, just one year after covid hit the US.
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Reports-Positive-Phase-3-Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventila-O9C2T.pdf
Even more significant was the earlier announcement that the company was recalling their loaned shares.
"The penny stock company said just days before Shkreli's purchase that "it would wind down operations and liquidate assets, adding that any expectation of strategic alternatives were "highly unlikely." The company said it would discontinue two development programs, in Phase 1 and Phase 2 stage, adding it would not be able to file its Form 10-Q for the third quarter."
Shkreli has since been named the chief executive officer of KaloBios. A stock that at one point traded below $0.50 per share this year hit a high of $45.82 last week. On Thursday afternoon, Shkreli some other interesting news.
"I spoke with my counsel & advisers and decided to stop lending my $KBIO shares out until I better understand the advantages of doing so," Shkreli said. "I apologize for any inconvenience this may create in lending markets and I will probably resume lending at some point. Happy Thanksgiving!"
https://finance.yahoo.com/news/why-martin-shkreli-no-longer-155239570.html
So I share your excitement that we could be seeing, "Exactly the same..." things that we have seen before.
VWAP= $ 0.0001 Total$Vol= $ 3
Exactly the same as yesterday.
I kinda like my PA. She finally made it into the exam room 30 minutes late. She took in my skrungy appearance and listened as I told her how I felt that I had been hit by a truck. She knows that I don't like taking medicine or seeing doctors. She did offer to recommend some OTC drugs, but she could have just as easily been offering to get me a cherry sucker. But what else should she do? She had my lab results which she described as "perfect." And she set my next appointment in July.
I think she was just bemused by my not feeling well, because I just don't seem to get sick. I'm starting to feel better this morning.
VWAP= $ 0.0001 Total$Vol= $ 3
Three-buck Chuck.
Big pharma is preparing to lose revenue from blockbuster drugs https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Will today be the day that I need lenz? It was last Monday that I had a lab appointment at my doctor's office, and I have felt that I was hit by a truck for a week now. I'm scheduled to see the doctor for a follow-up today.
There are no FDA approved treatments for covid in the US.
I could get Paxlovid, but I have no confidence in that Pfizer product that researchers are finding 10X higher reinfections than the company reports. I'm not going to let the doctor prescribe it for me.
"The U.S. Food and Drug Administration (FDA) hasn’t approved any drugs that can treat COVID-19..."
https://www.yahoo.com/lifestyle/covid-19-antiviral-drugs-promise-200554966.html
Talk about a reality check. I'm really hoping that if lenz is used as a Novavax vaccine adjuvant, then the medical community will catch on to using lenz once covid is diagnosed, even before CRP levels are elevated to the point where patients have to be hospitalized.
"When a young, healthy person in the U.S. catches COVID-19, there’s not much they can do except stay home and rest." That wouldn't have worked in 2020, and I don't think that guidance will work in future variants. especially when mutations can be manipulated.
A second Statement of acquisition of beneficial ownership has been filed for Novavax in the last two days, this one filed by BlackRock.
https://www.sec.gov/Archives/edgar/data/1000694/000108636424004696/us6700024010_012624.txt
Thanks for sharing your exit strategy, eb. Here are my open orders.
GBLX
G B SCIENCES INC
Open
Sell 4,700 Limit $2.00 GTC
Exp 07/22/2024
HGENQ
HUMANIGEN INC
Open
Sell 6,500 Limit $200.01 GTC
Exp 07/02/2024
HGENQ
HUMANIGEN INC
Open
Sell 3,500 Limit $200.00 GTC
Exp 07/02/2024
Of interest is that Li Huang is described as Application and Data Manager at NIH/NICHD Rockville, Maryland, United States. He is also the Petitioner in the District Court Case.
https://www.linkedin.com/in/li-huang-ab95437
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
And just to keep apparently related case info together, here again is the link to the Appeals Court.
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
I'm totally lost by not seeing SEC enforcement actions in terms of either an Admin Proceeding or a Litigation Release. I hope you can get a positive fill on your highest priced sell orders. I feel somewhat reassured if the bankruptcy terms are agreeable to management.
So, as you have advised and as I have done for many other stocks over the years, I have some standing GTC limit orders in two of my accounts for HGENQ. One has 50,000 shares, total, spread in three orders @ $30, $40, and $50. The other has four orders @ $20, $30, $40, and $50 totaling 100,000 shares. The orders in both accounts expire on July 3rd. Schwab would not let me put higher prices on them. Also, they would not let me put in orders in 4 other family accounts that I manage. So, I am ready to get some profits IF the squeeze happens. If they all go off and we go to $100 or $200 per share as you have advocated, I will still have over 150,000 shares to profit from the higher prices. So....... I am hoping with you.
But it's not JUST a short squeeze. I think the pieces of our transformation are in place to completely reinvent who we are, with some type of regulatory approval, and a partnership that will result in billions of revenue dollars.
Okay, so you are referring to a squeeze. My POV they had ample opportunity for 5months to initiate a squeeze and if it hasn't happened up to this point i dont know as it is going to happen. I hope I am wrong as that squeeze would certainly give the stalking horse ample funds to secure the company against other potential bidders.
The precedent would be the previous recall of our loaned shares. Evidence of that preparation would be in the design of our share structure.
How so Jay? Are you referring to a share buyback or something entirely different? Please explain the logic trail you are following and is there precedent of it occurring?
Covid changed everything. I wouldn't want to see management dedicate one more day, or one more dollar, exclusively focused on getting lenz approved, "instead of" simultaneously safeguarding shareholders and our intellectual property.
We're about to see one of the biggest revenue payouts in history, claimed by the smallest company ever to succeed.
This seems like a lot. I wonder how much work was going on putting together and planning the stalking horse bid paperwork and securing financing for it instead of a good faith effort to try right the ship and get Lenz approved while collecting our CEO salary after July.
LOL $250K would do a lot for me right about now. The other three million I will hold for a lot more! :)
I wouldn’t let them off that easy!
I might keep looking, but I don't see any enforcement actions filed by the SEC either as an Admin Proceeding, or as a Litigation Release, against Dale.
I found a record filed in the US District Court for the Eastern District of Pennsylvania on August 11, 2023.
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
And I found a record of Dale's Appeal filed in the U.S. Court of Appeals, Third Circuit, on October 4, 2023
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
Several of the docketed items are sealed.
So I can't make a connection between these proceedings and the Humanigen bankruptcy case. But I feel confident that connection exists, and by Dale prevailing in his Appeal, that will bode well for the bankruptcy case, if not obliterate it.
'Stocktwits' poster TwongStocks notes, "Seems the parties have worked out their issues. Per para 5, the US Trustee and UCC do not object to this revision. Taran does not consent or object. So as long as there are no more objections, the Court will likely finalize the bid procedures order."
https://stocktwits.com/TwongStocks/message/559238962
We'll have to see if the issues that were worked out relate to Dale's Appeal, as I suspect to be the case.
If they are short and in trouble, I am a nice guy as I have 1 million shares up for grabs at .25 cents a share if they need to cover.
I will hang on to the rest to see how this plays out, but for now I would be happy with a cool $250K in my account! :))
Hopefully it will be lucky for all of us who are still in this. ;) I know I think I really pissed them off after I received that letter which I replied to them telling them that this rule only applies to listed securities. OTC stocks are not listed securities, and that I don't have $20 million in my account yet.
Maybe after the bankruptcy reorganization I will see twenty million in my account with these 4 million shares! :))
After I made those purchases, I noticed all of the new posters showing up here posting on how worthless this stock is right after I got filled for those 4 million shares. It was a break in the matrix that allowed these orders to get filled. LOL
Executed Buy 236,276 HGENQ Limit Day 01/05/24 11:12:10 AM EST 236,276 0.0001 4.95
Executed Buy 763,724 HGENQ Limit Day 01/05/24 11:12:24 AM EST 763,724 0.0002 0.00
Executed Buy 749,970 HGENQ Limit Day 01/05/24 02:25:02 PM EST 749,970 0.0003 4.95
Executed Buy 483,596 HGENQ Limit Day 01/05/24 02:47:59 PM EST 483,596 0.0004 0.00
Executed Buy 500,000 HGENQ Limit Day 01/05/24 03:52:22 PM EST 500,000 0.0003 4.95
Executed Buy 1,000,000 HGENQ Limit Day 01/05/24 03:54:59 PM EST 1,000,000 0.0003 4.95
Wow, I’ve never seen that and I’ve traded plenty of sub penny stocks with orders of 10 million plus shares. Something caught their attention with your trade and it was probably the glitch that allowed your trade to go through!
Lucky glitch for you….hopefully!
You are right we definitely control a lot of the OS. It's probably good that the brokerages updated the ticker with the Q added so that I could not buy anymore. LOL I had orders in on Monday January 8th, but the brokerages cancelled my buy orders due to being on the expert market.
I didn't realize with 4 million shares that I am like a 4% owner. I do not want to hit that 5% ownership. So, I am good right where I stand.
I actually have 4,100,000 shares as I bought 100,000 shares around .012 before it went to the expert market. I paid more for the 100,000 shares than I did the 4 million shares. Crazy when you think about it.
I think I pissed them off because shortly after I bought those shares, I received this letter?
I have been trading pennies for years and never even heard of this RULE before?
January 8, 2024
*XXXXXXXXX DCMSPE XXXXXXXXXXX*
XXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXX
ACCOUNT NUMBER: XXXXXXXXXX
1 of 1
PLEASE REVIEW ACTION MAY BE REQUIRED: LARGE TRADER NOTIFICATION
During a recent review, we noticed that your trading activity through E*TRADE exceeded the minimum activity level
established by SEC Rule 13h-1 (the “Rule”). In addition, we do not have a Large Trader Identification Number
(“LTID”) on record for your account(s).
What you need to know:
The Rule requires persons or entities to obtain an LTID from the SEC when transacting in National Market System
(“NMS”) securities equal to or in excess of certain thresholds. The minimum activity level is:
• Two million shares or $20 million during any calendar day; or
• 20 million shares or $200 million during any calendar month.
For options, the equivalent values are determined by:
• Multiplying the number of contracts by 100 when calculating the quantity of shares; or
• Multiplying the quantity of shares by the premium paid when calculating the fair market value.
What you need to do:
Generally, the Large Trader Rule requires you to file Form 13H and make certain disclosures to the SEC. For more
information, please refer to the SEC’s Large Trader Reporting FAQs:
https://www.sec.gov/divisions/marketreg/large-trader-faqs.htm
If you determine that you qualify as a Large Trader and register with the SEC, please provide your LTID to E*TRADE.
You may do so by calling us at 800-ETRADE-1 (800-387-2331) or by sending us a secure message.
Additional information:
• To send a secure message, log on to your account at etrade.com and click “Customer Service” at the top of
the page. Then, click “Contact Us” and compose your message.
• Form 13H is an online electronic form available through the SEC’s website to persons with EDGAR system
access. Details on how to file Form 13H through EDGAR can be viewed at:
https://www.sec.gov/edgar/filer-information
Please note that the information contained herein is not to be construed as legal advice.
As always, thank you for choosing E*TRADE. It is our privilege to serve you.
P O BOX 484 • JERSEY CITY NJ 07303-0484
Morgan Stanley Smith Barney LLC. Member SIPC.
Well we can combine our shares and flex some muscle as significant shareholders in any upcoming lawsuits as this plays out lol!
That's why we are here! You never know how these bankruptcy plays will turn out?
I was very pleased with the chapter 11 filing verses the 7 filing which would have wiped out the common shareholders.
With a chapter 11 filing we still stand a chance.
With the algorithms giving me 4 million shares at .00027 average I can afford the risk to wait this out! :)
Same boat as me, I picked up a few million shares just under .02….I’ve seen crazier things happen, just never had shares when they did lol!
Come to think of it, I did have 100,000 shares during that time period, that’s worth almost $500 I guess.
I know that these new shares are not eligible for that lawsuit and the .047 cents per share. I also did receive one of those cards from back when I was trading HGEN in that time frame. I had already sold my shares with some profit back then, so I just threw out that card for the lawsuit.
My hopes are that they go through the chapter 11 reorganization process and the HGEN shares get to stay intact and they bring it back off of the greys.
That's where the big payday could come into play?
Even if it just becomes just a shell with an OS of 119 million shares this will have some signifficant value when or if it is bough out and brought back to pink current status?
For me this it a total lotto play. I honestly do not expect to win here.
If I do it will be a total surprise!
Have a Great Day Everyone!!!
Is State Street reflecting shares of Humanigen being transferred to Novavax?
https://fintel.io/so/us/hgen/state-street
https://www.sec.gov/Archives/edgar/data/93751/000009375124000204/Novavax_Inc.txt
Heck if I know.
To be honest with you, I've been 'off' the whole week so far, all because I had to break from my routine for a lab appointment at my doctor's office at 10am Monday. I can only imagine that that was the latest appointment time they had available. My follow-up with my PA is at 3pm this coming Monday, not another god-awful morning excursion, which I just don't do normally. And as it would happen, I woke up at 1am Monday. Didn't eat anything because I seem to fall asleep after eating. So after the lab work, I went to the post office, Dollar General (all in the same block), and hit a McDonald's drive-thru at the next exit, since I was hungry.
By the time I got home from my grueling endeavor, I managed to develop muscle pain in my back. It ruined my appetite. So I tried to sleep it off, to no avail. Finally, I remembered that I have extra-strength Tylenol, which I hardly ever take.
Of course, this is when Humanigen decides to juggle two lawsuits at the same time. And two offers, from the DIP lender, and the tort lawyer.
Dang, I'm lucky to be alive after the terrible ordeal this week has proven to be for me.
I’m following you now, you are basing it on the $2 milly from Durant not the $3milly from the settlement, makes sense.
Yes, I conceded to your excellent point. Nevertheless, DTG is positioned to enter a sell order with Durrant's offer as a benchmark. I don't think he will do that, but it's got to be nice to be positioned as he is.
"New long COVID study uncovers high inflammation in patients as Senate calls for more research on 'crisis'"
ASHLEY RIEGLE
Wed, January 24, 2024
https://www.yahoo.com/gma/long-covid-study-uncovers-high-011010645.html
If Long Covid has now advanced to the crisis stage, and since it is caused by high inflammation, how much longer can lenz be ignored as the premier treatment therapeutic for this indication? Or, HAS lenz been ignored? I recall that lenz was submitted as a treatment candidate for this indication. Is Long Covid going to be a new indication for lenz, causing regulatory approval and further stimulating investor demand ahead of the company's recall of their loaned shares? Is this why Durrant is both the stalking horse bidder, as well as the DIP lender?
He won’t be getting .047 a share based on his share purchase after the cutoff date for those shares….
I bought shares at under .02, would be a nice gain of course but I don’t qualify for the settlement and nether does he if I’m reading it right.
Yes, it may be laughable. But not so much when compared to an average cost basis of $0.00027, for millions of shares. I'm very happy for DTG.
Yeah I was surprised when I got the postcard but realized it didn’t apply to the share I bought after the delisting.
It does affect shares I had during the time frame.,,but .047?? Thats laughable
No, you're correct, sosjtb. Thank you for clarifying that. I screwed up a couple of things lately, like buying GB Sciences stock, when I was trying to buy my first ETF. And I did not comply with the procedure for requesting exclusion from the Class Action litigation. They explained some of the reasoning that a shareholder may decide to exclude himself from litigation. But they failed to note that someone like me would be more inclined to join a suit against the tort lawyer. We'll see how that develops.
Are you referring to the settlement of .047 a share for the $200K pay out Jay? If so I believe that only applies to holders of a specific timeframe ending in July 2022 I think.
I don't know who would provide the locates for ~4M shares for $11K. But you could be right. I certainly share your disdain for naked shorters, and I feel proud of the fact that the SEC actually charged Penson Financial for Naked Shorting.
Well Jay, My opinion is that he got more counterfeit shares that the shorts sold in a naked affair. As you said again, they are in big doo-doo when they have to replace them. But maybe your opinion is the right one.
You vacillated, but you ultimately bit the bullet and you have a guaranteed payout of just under $200K. So I hope your exit strategy may not necessarily be binary, and that you don't "go home broke."
Your acquisition certainly sent a signal to the shorts that the bankruptcy has not deterred retail interest in this stock.
But I think the Q suffix was timed to coincide with management's conclusion of the accumulation of shares in preparation for the recall of the company's loaned shares. Note the share volume in the two days preceding the Q designation on the 5th.
https://ih.advfn.com/stock-market/USOTC/humanigen-ce-HGEN/historical/more-historical-data
My guess is that management provided those shares for you, and that's why I think our ownership of the company may have been reduced from 92% to 89%. I think it was a very generous and gracious display of management's consideration of a shareholder. I think they provided just enough shares to keep you from filing Beneficial Ownership documentation.
I mentioned the 89-92% control in a separate post. "I've been wondering if Dale's Appeal hearing might force disclosure regarding the amount of Humanigen stock controlled by the company, which I think could range from 89-92%, which would cause one heck of a short squeeze, if the company recalled their loaned shares, and would mean that the bankruptcy petition could be withdrawn."
The company may not want to withdraw the bankruptcy petition. But I mention it because I doubt that the objections being filed are considering this possibility.
However, I think that our partners are likely aware of the company's strategy. After all, they are incurring most of the trial costs for CAR-T, CMML, and AGvHD.
Of particular note is the lack of recognizing the covid opportunity. Management has not chosen to recognize a partnership for this indication, which I think will result in more revenue, and save more lives, than all of the other indications combined. I've made clear my own opinion that Novavax may prove to be a partner for us by using the lenz vaccine cocktail, and expanding our market upstream of hospitalized covid patients, to include the prophylaxis use of lenz.
Shareholders are on the threshold of life-changing reward, and the whole world is on the threshold of having a life-saving covid vaccine and therapeutic.
TD Ameritrade and e-trade
Do you mind sharing which platforms you used?
When the Q designation comes off there maybe another window of opportunity to pick up shares here. LOL
It took their systems a day to catch up to the Q designation. I was able to place trades across multiple trading platforms. However, the next trading day everything was rejected.
Hahahahah, just asking to see if I could find a way to pick up more shares in the USA.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43428
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |